Weizao Chen

USPTO Granted Patents = 13 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

10 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

3 out of 5

Zhejiang Shimai Pharmaceutical Co., Ltd.

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12325758 - Protease cleavable bispecific antibodies and uses thereof (2025-06-10),

2. 12325757 - Protease cleavable bispecific antibodies and uses thereof (2025-06-10),

3. 12012455 - Human monoclonal antibodies specific for FLT3 and uses thereof (2024-06-18),

4. 11339218 - Human monoclonal antibodies against LAG3 and uses thereof (2022-05-24),

5. 11236171 - Human monoclonal antibodies specific for FLT3 and uses thereof (2022-02-01),

6. 10647754 - Stabilized single human CD4 domains and fusion proteins (2020-05-12),

7. 10472412 - Bispecific multivalent fusion proteins (2019-11-12),

8. 10287340 - Anti-HIV domain antibodies and method of making and using same (2019-05-14),

9. 9657096 - Human domain antibodies against components of the human insulin-like growth factor (IGF) system (2017-05-23),

10. 9181327 - Anti-HIV domain antibodies and method of making and using same (2015-11-10),

11. 9127056 - Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II) (2015-09-08),

12. 9056907 - Human domain antibodies against components of the human insulin-like growth factor (IGF) system (2015-06-16),

13. 8911728 - High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins (2014-12-16),

Title: Weizao Chen: Pioneering Innovator in Antibody Development

Introduction

Weizao Chen, a prominent inventor based in Frederick, MD, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 11 patents, Chen's work primarily focuses on human monoclonal antibodies and their applications in cancer treatment, showcasing his dedication to innovating solutions for pressing medical challenges.

Latest Patents

Weizao Chen's recent innovations include two groundbreaking patents that have the potential to revolutionize cancer treatment. The first patent, titled "Human monoclonal antibodies specific for FLT3 and uses thereof," details antibodies that specifically bind to the Fms-like tyrosine kinase 3 (FLT3). This innovation is particularly relevant for the diagnosis and treatment of FLT3-associated cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The second patent, "Human monoclonal antibodies against LAG3 and uses thereof," presents isolated monoclonal antibodies with high affinity for LAG3. These antibodies can enhance antigen-specific T cell responses and are significant for developing therapies aimed at stimulating immune responses and treating cancer.

Career Highlights

Throughout his career, Weizao Chen has collaborated with renowned organizations, including the United States of America, represented by the Secretary of the Department of Health and Human Services, and Zhejiang Shimai Pharmaceutical Co., Ltd. His expertise in antibody development has earned him recognition within the scientific community, paving the way for advancements in cancer therapies.

Collaborations

Chen has worked alongside talented individuals, including Dimiter Stanchev Dimitrov and Tao Fu, contributing to various innovative projects. These collaborations highlight the importance of teamwork in scientific research and innovation, as they combine diverse skills and knowledge to tackle formidable challenges in healthcare.

Conclusion

Weizao Chen continues to push the boundaries of medical science through his innovative antibody research. His dedication to developing novel therapeutics demonstrates the vital role of inventors in advancing healthcare solutions. With his significant contributions and ongoing efforts, Weizao Chen is poised to make a lasting impact on the field of oncology and beyond.

This text is generated by artificial intelligence and may not be accurate.